Cabazitaxel is a semisynthetic taxane with poor affinity for MDR1 compared with taxol and is approved for use in the treatment of patients with hormone-refractory metastatic prostate cancer.100. This evidence concerns the gene ABCB1 and metastatic prostate carcinoma.